Elevated serum ELABELA and SERPINA3 as novel biomarkers to predict poor prognosis in Egyptian chronic lymphocytic leukemia patients

Abstract

Abstract Background Chronic lymphocytic leukemia (CLL) is the most common kind of adult leukemia worldwide. Increased expressions of serpin peptidase inhibitor, clade A member 3 (SERPINA3) and apelin receptor early endogenous ligand (ELABELA) have been observed in various malignancies. However, there is little information on their clinical importance in CLL. Patients and methods The study included 67 newly diagnosed CLL patients and 66 healthy individuals as a control group. This study was conducted at the Oncology Center, Mansoura University, Mansoura, Egypt from April 2020 to March 2022. Serum levels of SERPINA3 and ELABELA were determined using an enzyme-linked immunosorbent assay. Results This study found that serum levels of SERPINA3 and ELABELA were significantly higher in CLL patients than in the control group with P less than 0.001 and P=0.001, respectively. SERPINA3 and ELABELA were found to be independent risk factors for CLL. In CLL patients, increased serum levels of SERPINA3 and ELABELA were associated with advanced staging, reduced progression-free survival, and overall survival. Conclusion Serum SERPINA3 and ELABELA could be used as prognostic biomarkers to predict poor prognosis in CLL patients. So, inhibition of SERPINA3 and ELABELA may be a promising therapeutic target for CLL treatment.